Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

N4 Pharma (THAT) Share Price & Analysis

7 Followers

THAT Stock Chart & Stats

GBX 0.58GBX 0.00(0.00%)
At close: 4:30 PM GMT
0.55 p0.6 p0.65 pAug 17Sep 1Sep 14Sep 29Oct 12Oct 26Nov 9
Day’s Range
GBX 0.55 - GBX 0.60
52-Week Range
GBX 0.40 - GBX 0.95
Previous Close
GBX 0.58
Volume
N/A
Average Volume (3M)
576.99K
Market Cap
GBP 14.18M
Enterprise Value
GBP 4.01M
Total Cash (Recent Filing)
GBP 1.50M
Total Debt (Recent Filing)
GBP 0
Price to Earnings (P/E)
―
Beta
1.33
Next Earnings
Feb 24, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Proprietary Nuvec Platform

Nuvec gives N4 Pharma a defined technology platform that can be applied across multiple drug-delivery markets, including vaccines and oncology. If development and external collaboration progress, the platform could support several commercialization paths rather than relying on one single therapeutic product.

Debt-free Balance Sheet

Having no debt reduces solvency and refinancing pressure while preserving flexibility during the company’s development stage. This structure avoids interest obligations and gives management more capacity to direct available resources toward research, partnerships and platform development as opportunities emerge.

Narrowing Cash Outflows

Although N4 Pharma remains cash-burning, the reduction in operating and free-cash-flow outflows versus 2023 indicates some improvement in cash discipline or spending intensity. If maintained, lower burn could extend financial runway and reduce the pace at which additional funding may be required.

Bears Say

Persistent Unprofitability

Deep and recurring operating and net losses show that the current business is not economically self-sustaining. Margins substantially below zero indicate costs remain far above the revenue base, creating a durable execution challenge until products, partnerships or licensing generate materially larger income.

Ongoing Cash Burn

Persistent negative operating and free cash flow means accounting losses are translating into actual cash consumption rather than being mainly non-cash charges. Continued development therefore depends on available funding and successful commercial progress, increasing the financial consequences of delays or setbacks.

Small, Volatile Revenue Base

A very small and fluctuating revenue base provides limited evidence of repeatable commercial traction and makes results difficult to forecast. The reported zero gross profit in 2025 further questions current revenue quality, while fixed development costs continue to overwhelm the top line.

N4 Pharma News

THAT FAQ

What was N4 Pharma’s price range in the past 12 months?
N4 Pharma lowest share price was 0.40 p and its highest was 0.95 p in the past 12 months.
What is N4 Pharma’s market cap?
N4 Pharma’s market cap is £14.18M.
When is N4 Pharma’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were N4 Pharma’s earnings last quarter?
N4 Pharma released its earnings results on Sep 30, 2026. The company reported -0.001 p earnings per share for the quarter.
Is N4 Pharma overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does N4 Pharma pay dividends?
N4 Pharma does not currently pay dividends.
What is N4 Pharma’s EPS estimate?
N4 Pharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does N4 Pharma have?
N4 Pharma has 1,775,721,000 shares outstanding.
What happened to N4 Pharma’s price movement after its last earnings report?
N4 Pharma reported an EPS of -0.001 p in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of N4 Pharma?
Currently, no hedge funds are holding shares in GB:THAT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology